Dorsey Wright & Associates acquired a new stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,772 shares of the medical equipment provider’s stock, valued at approximately $4,682,000. Dorsey Wright & Associates owned approximately 0.06% of ABIOMED as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABMD. Koch Industries Inc. increased its holdings in shares of ABIOMED by 40,431.3% during the second quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock valued at $794,000 after acquiring an additional 797,305 shares in the last quarter. Baillie Gifford & Co. increased its holdings in shares of ABIOMED by 17.9% during the second quarter. Baillie Gifford & Co. now owns 1,971,690 shares of the medical equipment provider’s stock valued at $282,543,000 after acquiring an additional 299,255 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of ABIOMED by 99.8% during the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock valued at $81,626,000 after acquiring an additional 241,868 shares in the last quarter. FMR LLC bought a new stake in shares of ABIOMED during the second quarter valued at approximately $32,609,000. Finally, Renaissance Technologies LLC increased its holdings in shares of ABIOMED by 33.6% during the second quarter. Renaissance Technologies LLC now owns 893,223 shares of the medical equipment provider’s stock valued at $127,999,000 after acquiring an additional 224,523 shares in the last quarter. Hedge funds and other institutional investors own 90.46% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/11/13/27772-shares-in-abiomed-inc-abmd-acquired-by-dorsey-wright-associates.html.
In other ABIOMED news, Director Paul Thomas sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total value of $1,547,100.00. Following the completion of the transaction, the director now owns 12,172 shares in the company, valued at approximately $1,883,130.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total value of $1,910,268.24. The disclosure for this sale can be found here. Insiders have sold 61,646 shares of company stock valued at $10,003,780 in the last quarter. 7.00% of the stock is currently owned by corporate insiders.
Shares of ABIOMED, Inc. (NASDAQ ABMD) traded down $0.33 during trading on Monday, reaching $195.21. The company had a trading volume of 176,400 shares, compared to its average volume of 336,893. ABIOMED, Inc. has a 1-year low of $103.53 and a 1-year high of $198.29. The company has a market capitalization of $8,600.00, a P/E ratio of 125.14, a P/E/G ratio of 2.60 and a beta of 0.23. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. ABIOMED’s revenue was up 28.9% compared to the same quarter last year. sell-side analysts anticipate that ABIOMED, Inc. will post 2.38 EPS for the current fiscal year.
Several equities research analysts have recently commented on ABMD shares. Jefferies Group LLC boosted their price objective on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a report on Friday, August 4th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. SunTrust Banks, Inc. started coverage on ABIOMED in a report on Friday, September 29th. They set a “buy” rating and a $195.00 price objective for the company. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price objective on shares of ABIOMED in a report on Tuesday, August 29th. Finally, Zacks Investment Research upgraded ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price objective for the company in a report on Monday, October 30th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $185.38.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.